XOMA as of Nov 4 · 13:00 ET
XOMANasdaqPharmaceutical Preparations

XOMA Royalty Corp · Brief

Next report

5 days

Nov 9 · before openest.Q3 FY26

Expected move

No implied move.

Implied vs realized

8 reportsHistory
0 of 8≥ implied
avg implied
±16.2%
avg realized
±6.0%
Aug 13 '24±17.0%▲+14.40%×0.85
Nov 7 '24±15.9%▼−6.96%×0.44
Mar 17 '25±18.9%▲+0.77%×0.04
May 13 '25±16.7%▲+10.89%×0.65
Aug 13 '25±9.9%▲+8.54%×0.86
Q3 FY25±12.3%▼−2.52%×0.21
Mar 2 '26±22.0%▲+2.66%×0.12
Q1 FY26±17.0%▲+1.30%×0.08
quarterimplied−25%0+25%realized×
Q1 FY26±17.0%▲+1.30%×0.08
Mar '26±22.0%▲+2.66%×0.12
Q3 FY25±12.3%▼−2.52%×0.21
Aug '25±9.9%▲+8.54%×0.86
May '25±16.7%▲+10.89%×0.65
Mar '25±18.9%▲+0.77%×0.04
2 older reports
Nov '24±15.9%▼−6.96%×0.44
Aug '24±17.0%▲+14.40%×0.85
Shaded = implied · tick ▲▼ = realized · × = |realized| ÷ impliedSource: options EOD · implied at prior close · realized close to close

Bull & bear

Nov 9 report · est.

Bull2 of 3

5disclosed supplier and customer tiesSEC filings
86managers reporting a position in the latest quarterly filings13F · Jun 30 '26

Bear2 of 3

8 of 8recent reports moved under the options implied rangeEarnings history
7managers holding the bulk of reported value13F · Jun 30 '26
AI captions · Nov 2 '26once per report · top 2 per case

Linked exposure

XOMA report session
× = co-movement · max 436dSource: SEC filings · market data

Latest changes

30 daysAll changes

No changes.

Your note

privateThesis 0 · Decisions 0 · Observations 0

No thesis.